Why MedTech Software Doesn't End at Go-Live: The Reality of Post-Market Compliance
The CE mark is on the wall. The FDA clearance came through. Your medical device software is live in hospitals, clinics, or in the hands of patients. Now what? For most MedTech and HealthTech companies, the answer to that question is dangerously unclear. Development teams move on to the next product. Regulatory affairs focuses on new markets. And the software running on real devices, in real clinical environments, is left to run itself. It won't.
The Misconception: Compliance as a Finish Line
There's a widespread assumption in medical device development that regulatory approval is the end of the compliance journey. Get the CE mark. Clear the FDA. Ship the product. Done.
This was never entirely true — but under MDR, IVDR, and the FDA's current Software as a Medical Device (SaMD) framework, it is categorically false.
Post-market surveillance is not a formality. It is a mandatory, ongoing obligation that begins the moment your product reaches its first user and continues for the entire commercial lifetime of the device.
What Post-Market Compliance Actually Requires
Under MDR and IVDR, manufacturers are required to maintain a Post-Market Surveillance (PMS) system that continuously collects and evaluates data from the field. This includes user feedback, clinical data, incident reports, and vigilance reporting to competent authorities when serious incidents occur.
For software-based medical devices and SaMD platforms, this gets more complex. Every software update — including security patches, bug fixes, and feature changes — must be evaluated against the original clinical and technical documentation. Depending on the nature of the change, a full or partial re-evaluation under IEC 62304 may be required before the update can be deployed.
The FDA's post-market cybersecurity guidance adds another layer: manufacturers must actively monitor for new vulnerabilities in their software stack, assess their severity in a clinical context, and deploy fixes within defined timeframes. This applies to third-party libraries and open-source components, not just code written in-house — which is where most teams are least prepared.
This is especially relevant for AI-enabled medical devices and SaMD platforms incorporating machine learning models. Under the EU AI Act, high-risk AI systems require continuous monitoring of model performance, data drift, and clinical validity — meaning post-market obligations for AI-driven HealthTech products go beyond standard software maintenance into active model lifecycle management.
The Software Lifecycle Problem
IEC 62304 defines software lifecycle processes for medical device software — from development through maintenance and decommissioning. What most companies discover after launch is that the maintenance phase is not lighter than development. In many ways, it is harder.
During development, the team is focused and the scope is controlled. Post-market, the software is live in environments you don't control, running on hardware configurations you didn't test, integrated with hospital systems that change independently of your release cycle.
A vulnerability disclosed in a widely-used library can require an emergency patch across all deployed versions. A change in a hospital's IT infrastructure can break an integration that worked fine in certification. A new cybersecurity requirement introduced by a regulatory update can require architecture changes to a product that's already in clinical use.
None of this is exceptional. All of it is normal. And none of it can be handled without a team, a process, and a documentation system that was built for it.
What Overstretched Internal Teams Get Wrong
The most common failure mode is not negligence — it's bandwidth. Internal engineering teams that built the product are also the ones expected to maintain it, while simultaneously developing the next version, supporting sales, and responding to clinical feedback.
Post-market compliance gets deprioritized. Updates get delayed. Documentation falls behind. And when a regulatory inspection arrives, or a serious incident needs to be reported, the paper trail isn't there.
Under MDR, this is not a minor issue. Failure to maintain post-market surveillance documentation can result in corrective action requirements, suspension of market access, or worse.
Build. Run. Evolve.
The companies that manage post-market compliance well are those that treat it as an engineering discipline, not an administrative task. They have dedicated processes for monitoring, patching, and documenting changes. They maintain their IEC 62304 software development files as living documents. They plan for software maintenance from the first day of development — not as an afterthought.
At Thaumatec, this is what long-term software lifecycle support means in practice. Not just keeping the lights on. Building the infrastructure that makes ongoing compliance manageable — so internal teams can stay focused on the core product, not on the operational burden of keeping it compliant.
Go-live is not the end. For medical device software, it's where the real work begins.
Thaumatec Tech Group provides audit-ready medical software development, IEC 62304-compliant engineering, post-market software lifecycle support, and cybersecurity management for MedTech and HealthTech companies operating in European and US regulated markets.*